Table 1. Baseline demographics and... | American Society of Hematology

Table 1.

Baseline demographics and disease characteristics

	Arm A (azacitidine + durvalumab) (n = 42)			Arm B (azacitidine monotherapy) (n = 42)
	No.	%	Median (range)	No.	%	Median (range)
Age, y			73.0 (46-83)			74.5 (57-89)
Sex
Male	28			30
Female	14			12
ECOG status
0		40.5			42.9
1		47.6			47.6
2		7.1			9.5
Hemoglobin, g/L			91.5 (54-125)			89.0 (38-129)
Transfusion burden, units/28 d			0.50 (0.0-7.0)			2.00 (0.0-8.0)
Platelet count × 10⁹/L			55.0 (5-347)			46.5 (11-355)
Low platelets (<100 000)	0			0
ANC × 10⁹/L			0.990 (0.03-14.22)			0.965 (0.10-7.99)
Low ANC (<100)
Band form	0			0
Segmented	29	76		33	83
Time since diagnosis, months			2.1 (0.4-93.8)			2.5 (0.0-42.1)
MDS
Primary		88.1			95.2
Secondary		11.9			4.8
IPSS-R risk category (central)*
Intermediate		2.4			7.1
High		42.9			38.1
Very high		47.6			50.0
IPSS-R cytogenetic risk category
Good/very good		26.2			26.2
Intermediate		21.4			19.0
Poor/very poor		52.3			54.7
Bone marrow blasts, %			10.00 (1.0-19.0)			8.00 (0.5-18.5)
Bone marrow blast % category
≤2		2.4			4.8
>2 to <5		11.9			7.1
5-10		35.7			57.1
>10		47.6			28.6
Main WHO classes*
RAEB-1		31.0			38.1
RAEB-2		40.5			35.7
Others		26.2			19.1
TP53 mutation status†
Wild-type		67.0			70.0
Mutated		33.0			30.0

	Arm A (azacitidine + durvalumab) (n = 42)			Arm B (azacitidine monotherapy) (n = 42)
	No.	%	Median (range)	No.	%	Median (range)
Age, y			73.0 (46-83)			74.5 (57-89)
Sex
Male	28			30
Female	14			12
ECOG status
0		40.5			42.9
1		47.6			47.6
2		7.1			9.5
Hemoglobin, g/L			91.5 (54-125)			89.0 (38-129)
Transfusion burden, units/28 d			0.50 (0.0-7.0)			2.00 (0.0-8.0)
Platelet count × 10⁹/L			55.0 (5-347)			46.5 (11-355)
Low platelets (<100 000)	0			0
ANC × 10⁹/L			0.990 (0.03-14.22)			0.965 (0.10-7.99)
Low ANC (<100)
Band form	0			0
Segmented	29	76		33	83
Time since diagnosis, months			2.1 (0.4-93.8)			2.5 (0.0-42.1)
MDS
Primary		88.1			95.2
Secondary		11.9			4.8
IPSS-R risk category (central)*
Intermediate		2.4			7.1
High		42.9			38.1
Very high		47.6			50.0
IPSS-R cytogenetic risk category
Good/very good		26.2			26.2
Intermediate		21.4			19.0
Poor/very poor		52.3			54.7
Bone marrow blasts, %			10.00 (1.0-19.0)			8.00 (0.5-18.5)
Bone marrow blast % category
≤2		2.4			4.8
>2 to <5		11.9			7.1
5-10		35.7			57.1
>10		47.6			28.6
Main WHO classes*
RAEB-1		31.0			38.1
RAEB-2		40.5			35.7
Others		26.2			19.1
TP53 mutation status†
Wild-type		67.0			70.0
Mutated		33.0			30.0

ANC, absolute neutrophil count; ECOG, Eastern Cooperative Oncology Group; RAEB, refractory anemia with excess blasts; WHO, World Health Organization.

Missing category not displayed.

Total of 76 patients across both arms.